Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284425 | 0.85 | GAA (0.41) | HPGDGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8000704 | 0.79 | HPGD (0.37) | HPGDGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13060991 | 0.79 | HPGD (0.37) | HPGDGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18077360 | 0.78 | KDM4E (0.49) | HPGDGAAMEN1KMT2ALMNA | |
| SCHEMBL13879940 | 0.78 | SIGMAR1 (0.37) | HPGDGAAMEN1KMT2AHTT | |
| SCHEMBL18474287 | 0.78 | PRKCI (0.38) | GAACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL13689913 | 0.78 | HTT (0.36) | GAAMEN1KMT2AHTTLMNA | |
| SCHEMBL12889181 | 0.77 | HPGD (0.45) | HPGDGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11855115 | 0.75 | NPC1 (0.42) | HPGDGAACYP1A2MEN1KMT2A | |
| SCHEMBL10314645 | 0.75 | ALDH1A1 (0.36) | HPGDKDM4ESMN1; SMN2ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-0238459-B1 | SUBSTITUTED INDOLOQUINOXALINES | Lundblad, Leif (SE) | 1992-04-15 | — | — | EP | disclosed |
| US-4990510-A | Viricides, anticancer agents | LEIF LUNDBLAD (BE) | 1991-02-05 | — | — | US | disclosed |
| EP-0238459-A1 | Substituted indoloquinoxalines | Lundblad, Leif (SE) | 1987-09-23 | — | — | EP | disclosed |
| WO-1987004436-A1 | SUBSTITUTED INDOLOQUINOXALINES | LUNDBLAD, LEIF (SE) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | HPGD 2801/4885GAA 4623/4885CYP1A2 65/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | HPGD 2801/4885GAA 4623/4885CYP1A2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.